Earnings summaries and quarterly performance for QUEST DIAGNOSTICS.
Executive leadership at QUEST DIAGNOSTICS.
James E. Davis
Detailed
Chief Executive Officer and President
CEO
CT
Catherine T. Doherty
Detailed
Executive Vice President, Regional Businesses
KK
Karthik Kuppusamy
Detailed
Senior Vice President, Clinical Solutions
ME
Michael E. Prevoznik
Detailed
Senior Vice President, General Counsel
SA
Sam A. Samad
Detailed
Executive Vice President, Chief Financial Officer
Board of directors at QUEST DIAGNOSTICS.
DM
Denise M. Morrison
Detailed
Director
GM
Gary M. Pfeiffer
Detailed
Director
LA
Luis A. Diaz, Jr., M.D.
Detailed
Director
RB
Robert B. Carter
Detailed
Director
TL
Timothy L. Main
Detailed
Director
TM
Timothy M. Ring
Detailed
Lead Independent Director
TC
Tracey C. Doi
Detailed
Director
VB
Vicky B. Gregg
Detailed
Director
WL
Wright L. Lassiter III
Detailed
Director
Research analysts who have asked questions during QUEST DIAGNOSTICS earnings calls.
David Westenberg
Piper Sandler
6 questions for DGX
Also covers: ADPT, AKYA, BLLN +13 more
Elizabeth Anderson
Evercore ISI
6 questions for DGX
Also covers: AGL, ALGN, CAH +23 more
EW
Erin Wright
Morgan Stanley
6 questions for DGX
Also covers: ALGN, BTSG, CAH +18 more
Jack Meehan
Nephron Research LLC
6 questions for DGX
Also covers: A, AVTR, BIO +17 more
Kevin Caliendo
UBS
6 questions for DGX
Also covers: AHCO, ALGN, AMWL +15 more
Patrick Donnelly
Citi
6 questions for DGX
Also covers: A, AVTR, BIO +21 more
PC
Pito Chickering
Deutsche Bank
6 questions for DGX
Also covers: ACHC, AHCO, AVAH +18 more
Michael Cherny
Leerink Partners
5 questions for DGX
Also covers: ACCD, ALGN, CAH +18 more
AB
Andrew Brackmann
William Blair & Company, L.L.C.
4 questions for DGX
Also covers: ADPT, AWH, BDSX +11 more
Luke Sergott
Barclays
4 questions for DGX
Also covers: A, AVTR, BRKR +19 more
Michael Ryskin
Bank of America Merrill Lynch
4 questions for DGX
Also covers: A, ALGN, AVTR +28 more
Tycho Peterson
Jefferies
3 questions for DGX
Also covers: A, AVTR, BIO +22 more
AB
Andrew Brackman
William Blair
2 questions for DGX
Also covers: BLLN, LH, VCYT
AH
Ann Hynes
Mizuho Financial Group
2 questions for DGX
Also covers: ARDT, BTSG, CI +17 more
EC
Eric Caldwell
Baird
2 questions for DGX
Noah Kava
Jefferies
2 questions for DGX
AD
Aaron David Izen
Bank of America
1 question for DGX
AK
Anna Krasinski
Barclays
1 question for DGX
LG
Lisa Gill
JPMorgan Chase & Co.
1 question for DGX
Also covers: AGL, CAH, CI +13 more
MH
Meghan Holtz
Jefferies Financial Group Inc.
1 question for DGX
Also covers: AHCO, AVAH, EHAB +4 more
MC
Michael Cherney
Jefferies Financial Group Inc.
1 question for DGX
Also covers: COR, LH
SD
Stephanie Davis
Barclays
1 question for DGX
Also covers: ACCD, CAH, COR +20 more
Recent press releases and 8-K filings for DGX.
Quest Diagnostics outlines growth strategy at JPM Healthcare Conference
DGX
Guidance Update
M&A
- Quest Diagnostics expanded network access with Elevance and secured partnerships with large corporate physician groups to drive growth in hospital labs, reference testing, collaborative lab solutions and life sciences services.
- Consumer-initiated testing grew from $30 million in 2021 to a $250 million run rate by Q4, with QuestHealth.com contributing $100 million and channel partners (e.g., Function Health, Whoop) adding $150 million.
- Focused on advanced diagnostics—including cardiometabolic, autoimmune and brain health—with commercial launch of the AB4240 Alzheimer's blood-based test for amyloid and tau biomarkers.
- Reaffirmed 2026 guidance: 4–5% total revenue growth, 75–150 bps operating margin expansion, 7–9% adjusted EPS growth, and $3–3.3 billion free cash flow after capex.
1 day ago
Quest Diagnostics outlines growth strategy and guidance at JPMorgan Healthcare Conference
DGX
Guidance Update
M&A
- Tests one-third of U.S. adults, completing ~220 million requisitions and directly drawing blood for ~80 million individuals in 2024; network spans 8,000 sites and covers 90% of lives with 80 billion data points ( ).
- Prevention and wellness represent ~33% of revenue; consumer-initiated testing surged from $30 million in 2021 to a $250 million run rate in 2025, led by QuestHealth.com’s $100 million business ( ).
- Operates in a $90 billion laboratory market (~2% of a $5 trillion healthcare spend); targets 4–5% organic revenue growth, 75–150 bps margin expansion, 7–9% EPS growth, and $3–3.3 billion free cash flow (2025–27) with capital allocated to M&A, dividends, and share repurchases ( ).
- $2.8 billion deployed in M&A over three years—including the $1 billion LifeLabs Canada acquisition—and growing co-lab hospital services from $800 million toward a $1 billion target by 2026 ( ).
1 day ago
Quest Diagnostics presents at 44th Annual J.P. Morgan Healthcare Conference
DGX
Guidance Update
M&A
Revenue Acceleration/Inflection
- Quest Diagnostics tested one-third of the U.S. adult population in 2024 with 217 million requisitions and 80 million blood draws, covering 110 million unique patients across 8,000+ locations.
- Prevention and wellness represents ~1/3 of revenue, while the consumer business rose from $30 million in 2021 to a $250 million run rate in Q4 2025 via QuestHealth.com ($100 million) and channel partners ($150 million).
- The company reaffirmed its 2026 outlook: 4–5% revenue growth, 75–150 bps operating margin expansion, 7–9% adjusted EPS growth, and $3–3.3 billion free cash flow (2025–2027) targets.
- Key investments include AI/automation (end-to-end lab systems, digital cytology), $2.8 billion in M&A (2023–25), and Project Nova to modernize the order-to-cash infrastructure.
1 day ago
Quest Diagnostics completes Michigan lab joint venture
DGX
M&A
New Projects/Investments
- Quest Diagnostics and Corewell Health complete laboratory services joint venture, Diagnostic Lab of Michigan, LLC, with Quest owning 51% and Corewell Health 49%
- Existing Quest and Corewell laboratories will continue providing services until a new 100,000-square-foot facility opens in Q1 2027
- Quest begins deploying Co-Lab Solutions across 21 Corewell Health hospitals, including supply chain, lab management, patient blood and anemia management, and lab analytics and stewardship
Jan 5, 2026, 1:58 PM
Quest Diagnostics discusses utilization, growth, guidance and strategic investments
DGX
Guidance Update
New Projects/Investments
- Quest highlighted sustained elevated test utilization, driven by expanded payer access, chronic disease screening, consumer health engagement, and growth in advanced diagnostics (cardiometabolic, autoimmune, women’s health, brain health, oncology).
- The direct-to-consumer channel (QuestHealth.com) is growing ~35% QoQ YoY, approaching $100 million in revenue; advanced diagnostics now contribute ~$1 billion and grow in the low double digits.
- For FY 2025, Quest expects organic revenue growth of 4.5%–5% (YTD 4.8%) and targets 75–150 bps of operating margin expansion over 2025–2027; Q4 typically sees a 50–100 bps seasonal margin decline vs. Q3.
- Project Nova, a lab IT transformation, carries $250–310 million in one-time costs (40% OpEx, 60% CapEx) over 6–7 years, with ~$20 million spend in 2025 and benefits anticipated from 2027.
- Management is planning for policy headwinds including potential PAMA cuts (~$100 million impact) and expiry of ACA exchange subsidies (~30 bps revenue/volume impact), and sees a >50% chance of a PAMA delay.
Dec 2, 2025, 8:15 PM
Quest Diagnostics outlines FY25 growth drivers and strategic initiatives
DGX
Guidance Update
New Projects/Investments
M&A
- Utilization remains resilient, with tests per requisition up to 4.3–4.4 from pre-COVID 3.8–3.9, driving 4.8% YTD organic revenue growth and full-year guidance of 4.5–5%.
- Direct-to-consumer channel questhealth.com is growing ~35% QoQ Y/Y, approaching $100 M in revenue, and expanding via partnerships (WHOOP, Oura, Hims & Hers) where Quest is the exclusive testing engine.
- Project Nova (lab information system overhaul) entails $250–310 M of one-time costs (40% OpEx, 60% CapEx) over 6–7 years, with <$20 M spent in 2025 and full benefits expected from 2027.
- 75–150 bps operating margin expansion target for 2025–27 is reaffirmed, with an expected 50–100 bps seasonal dip from Q3 to Q4.
- Acquisition and partnership pipeline focuses on physician outreach and lab services (Corewell +$200 M, Fresenius +$100 M), plus strategic tests like Haystack MRD (addressable $5–10 B market), with deals designed for >10% ROIC by year 3 and year-1 EPS accretion.
Dec 2, 2025, 8:15 PM
Quest Diagnostics highlights elevated utilization and strategic investments at Citi Healthcare Conference
DGX
Guidance Update
New Projects/Investments
Product Launch
- Maintained elevated utilization post-COVID with tests per requisition rising to 4.3–4.4 (vs. ~3.8–3.9 pre-COVID), driving organic revenue growth of 4.8% YTD and guided 4.5–5% for FY 25.
- Consumer channel revenue nearing $100 million, up 35% QoQ YoY, and advanced diagnostics tests (~$1 billion revenue) growing low double digits across cardiometabolic, autoimmune, women’s health, brain health and oncology.
- Investing $250–310 million in Project Nova (40% OpEx, 60% CapEx) over six to seven years, with initial FY 25 spend < $20 million and expected productivity benefits from 2027.
- Launched Haystack MRD test with Medicare PLA codes reimbursed at $3,900 baseline and $800 monitoring effective Jan 2026, expanded commercial reps to 35–40, targeting break-even by end-2026.
Dec 2, 2025, 8:15 PM
Quest Diagnostics reports Q3 2025 results and raises full-year guidance
DGX
Earnings
Guidance Update
New Projects/Investments
- Revenues increased 13.1% to $2.82 billion, with 6.8% organic growth; diagnostic services up 13.5%, and requisitions rose 12.5% year-over-year.
- Reported EPS of $2.16 and adjusted EPS of $2.60, with operating income at 13.7% of revenues (adjusted 16.3%); raised full-year revenue guidance to $10.96 billion–$11.0 billion, EPS to $8.58–$8.66, and adjusted EPS to $9.76–$9.84.
- Formed a lab services JV with Corewell Health (projected $1 billion annual COLAB Solutions revenue), launched Project Nova with Epic Systems, and expanded consumer channel partnerships with Whoop and Oura.
- Advanced diagnostics saw strong traction: autoimmune Analyzer growth, Quest AD-Detect volumes more than doubled, Haystack MRD earned FDA Breakthrough Device designation and Medicare reimbursement pending; targeting 3% annual cost savings via Invigorate automation.
Oct 21, 2025, 12:30 PM
Quest Diagnostics posts strong Q3 2025 results and raises guidance
DGX
Earnings
Guidance Update
New Projects/Investments
- Q3 revenue: $2.82 billion, up 13.1% year-over-year, including 6.8% organic growth.
- Adjusted diluted EPS: $2.60 per share, a 13.0% increase versus prior year.
- Expanded partnerships with Corewell Health via a lab services joint venture expected to generate ~$1 billion in annual revenues, and selected Epic for Project Nova to modernize order-to-cash processes.
- Full-year 2025 guidance raised: net revenue now expected at $10.96–11.00 billion and adjusted EPS at $9.76–9.84.
Oct 21, 2025, 12:30 PM
Quest Diagnostics reports Q3 2025 results
DGX
Earnings
Guidance Update
M&A
- Revenues were $2.82 B, up 13.1% year-over-year with 6.8% organic growth in Q3 2025.
- Adjusted operating margin expanded to 16.3% (from 15.5%) and adjusted EPS was $2.60 versus $2.30 a year ago.
- Cash from operations was $1.42 B year-to-date (up 63.1%); full-year 2025 guidance raised to ~$1.8 B with capex of ~$500 M.
- Full-year guidance lifted: revenues of $10.96 B–$11.00 B, reported EPS of $8.58–8.66 and adjusted EPS of $9.76–9.84.
- Growth fueled by clinical innovations, acquisitions (e.g., Fresenius testing assets) and consumer channel expansion via partnerships (WHOOP, Aura) plus a joint venture with CoreWell Health.
Oct 21, 2025, 12:30 PM
Quarterly earnings call transcripts for QUEST DIAGNOSTICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more